Solar Pharma’s This fall FY25 outcomes will seemingly present robust progress led by speciality medication. Income seen at ₹13,550 crore, revenue at ₹3,070 crore.>
Solar Pharma This fall FY25: Revenue Could Rise 18% YoY to ₹3,070 Cr
Leave a comment
